SB-743921

SB-743921, our second KSP inhibitor to enter clinical trials, is structurally distinct from ispinesib, Cytokinetics' most advanced anti-cancer drug candidate. SB-743921 is currently the subject of a Phase I/II clinical trial in Hodgkin and non-Hodgkin Lymphoma.

Development Status of SB-743921

Ongoing Clinical Trials Details

Phase I Details